A case study to compare the performances of several types of mixing in disposable bags with stainless steel bioreactors.
The article reviews strategies for firms with or without existing in-house capacities and the pros and cons for outsourcing bio/pharmaceutical development and manufacturing.
Evolving clinical trial research services give biopharmaceutical companies options for full and functional services.
An off-the-shelf, single-use perfusion system.
The authors describe considerations and best practices for meeting drug substance uniformity.
A case study to compare the performances of several types of mixing in disposable bags with stainless steel bioreactors.
The authors discuss how to develop a cost-effective thermally protective packaging system.
A plant-based expression system could provide greater speed and capacity at a comparatively low cost.
A hollow fiber matrix allows for efficient harvest of secreted proteins.
A case study to compare the performances of several types of mixing in disposable bags with stainless steel bioreactors.
These new analytical methods can reduce analysis and product development time.
Using a hollow microstructured transdermal system to deliver vaccine directly to the dermis.
The authors present the CMO's perspective on various potential sources of sponsor-CMO conflicts.
The authors discuss the evolution of the purification platform for manufacturing of mAb therapeutics.
Development requirements and regulatory guidance for biosimilars and biobetters.
Project: transfer a manual concentration/diafiltration process for siRNA production.
The authors examine several issues that will help streamline negotiations between a service provider and a cell-culture medium consumer.
Making chemically defined media work.
The presence of minute amounts of chelators can help minimize the degradation of monoclonal antibodies.
Making chemically defined media work.
An effective supplier-initiated change management process is discussed.
Evaluate and communicate risk to stakeholders.
Contract manufacturers must plan for increased analytical resources in development and quality control.
The authors outline qualification procedures for a process-critical piece of equipment.
The authors present lessons learned from a case study of the transfer of a cell culture biotherapeutic process to a CMO.
Safety concerns remain for developing replicating vectors based on the pathogen human immunodeficiency virus type 1.